Cartesian Therapeutics (RNAC) Other Non-Current Liabilities (2015 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Other Non-Current Liabilities data on file, last reported at $47000.0 in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities fell 97.67% year-over-year to $47000.0 in Q1 2026; TTM through Mar 2026 was $47000.0, a 97.67% decrease from a year earlier, with the FY2025 full-year figure at $141000.0, down 96.32% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $47000.0, down from $141000.0 in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RNAC reached as high as $33.5 million in Q3 2022 and fell as low as $47000.0 in Q1 2026.
• Historically, Other Non-Current Liabilities has averaged $10.0 million across 5 years, with a median of $5.7 million in 2023.
• Across the five-year window, Other Non-Current Liabilities surged 236.12% in 2023 and tumbled 97.67% in 2026, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $19.1 million in 2022, then slumped by 70.36% to $5.7 million in 2023, then plunged by 32.39% to $3.8 million in 2024, then tumbled by 96.32% to $141000.0 in 2025, then slumped by 66.67% to $47000.0 in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $47000.0 in Q1 2026, $141000.0 in Q4 2025, and $848000.0 in Q3 2025.